Your browser doesn't support javascript.
loading
Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers.
Mikulasova, Aneta; Kent, Daniel; Trevisan-Herraz, Marco; Karataraki, Nefeli; Fung, Kent T M; Ashby, Cody; Cieslak, Agata; Yaccoby, Shmuel; van Rhee, Frits; Zangari, Maurizio; Thanendrarajan, Sharmilan; Schinke, Carolina; Morgan, Gareth J; Asnafi, Vahid; Spicuglia, Salvatore; Brackley, Chris A; Corcoran, Anne E; Hambleton, Sophie; Walker, Brian A; Rico, Daniel; Russell, Lisa J.
Afiliação
  • Mikulasova A; Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, United Kingdom.
  • Kent D; Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, United Kingdom.
  • Trevisan-Herraz M; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, United Kingdom.
  • Karataraki N; Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, United Kingdom.
  • Fung KTM; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, United Kingdom.
  • Ashby C; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, United Kingdom.
  • Cieslak A; Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
  • Yaccoby S; Université de Paris (Descartes), Institut Necker-Enfants Malades (INEM), Institut National de la Santé et de la Recherche Médicale (Inserm) U1151, and Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, 75015 Paris, France.
  • van Rhee F; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
  • Zangari M; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
  • Thanendrarajan S; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
  • Schinke C; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
  • Morgan GJ; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
  • Asnafi V; NYU Langone Medical Center, Perlmutter Cancer Center, NYU Langone Health, New York, New York 10016, USA.
  • Spicuglia S; Université de Paris (Descartes), Institut Necker-Enfants Malades (INEM), Institut National de la Santé et de la Recherche Médicale (Inserm) U1151, and Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, 75015 Paris, France.
  • Brackley CA; Aix-Marseille University, Inserm, Theories and Approaches of Genomic Complexity (TAGC), UMR1090, 13288 Marseille, France.
  • Corcoran AE; Equipe Labellisée Ligue Contre le Cancer, 13288 Marseille, France.
  • Hambleton S; SUPA, School of Physics and Astronomy, University of Edinburgh, Edinburgh EH9 3FD, United Kingdom.
  • Walker BA; Lymphocyte Signalling and Development Programme, Babraham Institute, Cambridge CB22 3AT, United Kingdom.
  • Rico D; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, United Kingdom.
  • Russell LJ; Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, United Kingdom.
Genome Res ; 32(7): 1343-1354, 2022 07.
Article em En | MEDLINE | ID: mdl-34933939
Chromosomal translocations are important drivers of haematological malignancies whereby proto-oncogenes are activated by juxtaposition with enhancers, often called enhancer hijacking We analyzed the epigenomic consequences of rearrangements between the super-enhancers of the immunoglobulin heavy locus (IGH) and proto-oncogene CCND1 that are common in B cell malignancies. By integrating BLUEPRINT epigenomic data with DNA breakpoint detection, we characterized the normal chromatin landscape of the human IGH locus and its dynamics after pathological genomic rearrangement. We detected an H3K4me3 broad domain (BD) within the IGH locus of healthy B cells that was absent in samples with IGH-CCND1 translocations. The appearance of H3K4me3-BD over CCND1 in the latter was associated with overexpression and extensive chromatin accessibility of its gene body. We observed similar cancer-specific H3K4me3-BDs associated with hijacking of super-enhancers of other common oncogenes in B cell (MAF, MYC, and FGFR3/NSD2) and T cell malignancies (LMO2, TLX3, and TAL1). Our analysis suggests that H3K4me3-BDs can be created by super-enhancers and supports the new concept of epigenomic translocation, in which the relocation of H3K4me3-BDs from cell identity genes to oncogenes accompanies the translocation of super-enhancers.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Translocação Genética / Epigenômica Limite: Humans Idioma: En Revista: Genome Res Assunto da revista: BIOLOGIA MOLECULAR / GENETICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Translocação Genética / Epigenômica Limite: Humans Idioma: En Revista: Genome Res Assunto da revista: BIOLOGIA MOLECULAR / GENETICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido País de publicação: Estados Unidos